Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278791 | 1.00 | MEN1 (0.39) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL17374221 | 0.86 | MMP2 (0.40) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL17374218 | 0.86 | MMP2 (0.40) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL16071861 | 0.85 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL28295181 | 0.85 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL18897229 | 0.85 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL13618930 | 0.85 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30337446 | 0.84 | MAPT (0.35) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL19360747 | 0.82 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL16134084 | 0.82 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MEN1 4336/4885KMT2A 915/4885MAPT 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.